Patents by Inventor Joshua J. Rusbuldt

Joshua J. Rusbuldt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220168333
    Abstract: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Fei Huang, Joshua J. Rusbuldt, Aleksandra Rizo
  • Patent number: 11278561
    Abstract: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: March 22, 2022
    Assignee: Geron Corporation
    Inventors: Fei Huang, Joshua J. Rusbuldt, Aleksandra Rizo
  • Publication number: 20180036336
    Abstract: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 8, 2018
    Applicant: Janssen Biotech, Inc.
    Inventors: Fei Huang, Joshua J. Rusbuldt, Aleksandra Rizo